PepGen advances DM1 drug to highest dose after safety review
Tweet Send to a Friend
PepGen Inc. (Nasdaq: PEPG) said an independent Data and Safety Monitoring Board (DSMB) has recommended advancing its Phase 2 FREEDOM2-DM1 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


